Search results for "IPR"

showing 10 items of 1515 documents

Guía de práctica clínica del síndrome del intestino irritable con estreñimiento y estreñimiento funcional en adultos: tratamiento. (Parte 2 de 2)

2017

En esta Guía de práctica clínica analizamos el manejo diagnóstico y terapéutico de pacientes adultos con estreñimiento y molestias abdominales, bajo la confluencia del espectro del síndrome del intestino irritable y el estreñimiento funcional. Ambas patologías están encuadradas en los trastornos funcionales intestinales y tienen una importante repercusión personal, sanitaria y social, afectando a la calidad de vida de los pacientes que las padecen. La primera es el subtipo de síndrome del intestino irritable en el que el estreñimiento es la alteración deposicional predominante junto con dolor abdominal recurrente, hinchazón y distensión abdominal frecuente. El estreñimiento se caracteriza p…

medicine.medical_specialtyAbdominal painConstipation03 medical and health scienceschemistry.chemical_compoundMolestia abdominal0302 clinical medicineBloatingInternal medicinemedicineEnfermedades digestivasAdultos030212 general & internal medicineLinaclotideIrritable bowel syndromeMedicine(all)Estreñimiento funcionallcsh:R5-920business.industrydigestive oral and skin physiologySíndrome del intestino irritablePublic Health Environmental and Occupational HealthAtención PrimariaGeneral MedicineAbdominal distensionmedicine.diseaseLubiprostoneGuía de práctica clínicachemistryRoma IVFunctional constipation030211 gastroenterology & hepatologymedicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drugAtención Primaria
researchProduct

Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.

1997

Two hundred and fifty-five postmenopausal women with distal forearm bone mineral density (BMD) 1 SD below the mean value for normal age-matched postmenopausal subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matched placebo, according to a double-masked, parallel-group design. All patients also received a 1 g/day calcium supplement. Distal radius BMD and bone metabolism markers were measured at baseline, and every 6 months. Blood haematology and chemistry and physical parameters were monitored at the same time. One hundred and ninety-six patients completed 2 years of treatment. BMD changes from baseline were analysed according to valid comple…

medicine.medical_specialtyBone diseaseEndocrinology Diabetes and MetabolismOsteoporosisUrologyPlaceboBone and BonesBone remodelingchemistry.chemical_compoundBone DensityHumansMedicineOsteoporosis PostmenopausalAgedBone mineralCreatinineIntention-to-treat analysisbusiness.industryMiddle Agedmedicine.diseaseIsoflavonesSurgeryHydroxyprolineRadiuschemistryFemaleIpriflavonebusinessmedicine.drug
researchProduct

Antiapoptotic effect of calcitonin gene-related peptide on oxidative stress-induced injury in H9c2 cardiomyocytes via the RAMP1/CRLR complex.

2005

Calcitonin gene-related peptide (CGRP) plays an important role in the mediation of protective effects observed in situations such as ischemic preconditioning in rat hearts. In this study, we investigated in H9c2 rat cardiomyoblasts if the protective effect of CGRP could be linked to an inhibitory effect on the apoptotic pathway. We also determined the specificity of observed effects by treatment with adrenomedullin (ADM) in stress conditions generated by 100 microM hydrogen peroxide. Using MTT assays, we demonstrate that a pretreatment with CGRP decreases by half the loss of cell viability induced by H(2)O(2). CGRP inhibits phosphatidylserine externalization, caspase 3 activation and DNA fr…

medicine.medical_specialtyCalcitonin Gene-Related PeptideCaspase 3DNA FragmentationCalcitonin gene-related peptideReceptor Activity-Modifying Protein 2Receptor Activity-Modifying Protein 3Receptor Activity-Modifying ProteinsCell LineReceptor Activity-Modifying Protein 1Internal medicinemedicineAnimalsMyocytes CardiacViability assayMolecular BiologyReceptor activity-modifying proteinintegumentary systemChemistryCalcitonin Receptor-Like ProteinIntracellular Signaling Peptides and ProteinsMembrane ProteinsReceptors CalcitoninPeptide FragmentsRatsAdrenomedullinOxidative StressEndocrinologyGene Expression RegulationRAMP2ApoptosisRAMP1Multiprotein ComplexesIschemic Preconditioning MyocardialCardiology and Cardiovascular MedicineMioticsSignal TransductionJournal of molecular and cellular cardiology
researchProduct

Acute and chronic effects of clomipramine on isolation-induced aggression in male mice

1994

The behavioral effects of clomipramine were studied on an ethopharmacological model of aggression. A range of low doses (similar to those used in clinical practice: 1.5, 3, and 6 mg/kg) and a higher dose (24 mg/kg—more usual in animal experimentation) were administered to isolated male mice that confronted anosmic opponents in a neutral arena. Encounters were staged 30 min after acute treatment and either 30 min or 24 h after the last drug administration in the chronic (21-day) treatment. Significant behavioral effects were observed predominantly with the highest dose. Acute and chronic effects were similar in the sense that both decreased aggressive behavior and produced some impairment of…

medicine.medical_specialtyClomipraminePhysiologyAggressionRatónGeneral NeuroscienceDrug administrationMale miceDevelopmental psychologyEndocrinologyIsolation induced aggressionInternal medicinemedicineAgonistic behaviourmedicine.symptomAnimal testingPsychologymedicine.drugPsychobiology
researchProduct

International prescribing practices in obsessive-compulsive disorder (OCD)

2016

Objectives To assess rates of psychotropic medication use in patients with obsessive–compulsive disorder (OCD) in seven different countries on five continents and to compare these with international treatment guidelines. Methods Researchers in the field of OCD were invited to contribute summary statistics on the characteristics of their patients with OCD and on their incidence of psychotropic use. Consistency of summary statistics across countries was evaluated. Results The data came from Brazil (n = 955), Italy (n = 750), South Africa (n = 555), Japan (n = 382), Australia (n = 213), India (n = 202) and Spain (n = 82). The majority (77.9%; n = 2445) of the total sample of 3139 participants …

medicine.medical_specialtyClomipraminemedicine.drug_classbusiness.industryIncidence (epidemiology)Atypical antipsychoticPsychotropic medicationmedicine.disease030227 psychiatry03 medical and health sciencesPsychiatry and Mental health0302 clinical medicinePharmacotherapyNeurologymedicinePharmacology (medical)In patientNeurology (clinical)PsychiatrybusinessProspective cohort studyObsessive-compulsive disorder (OCD)030217 neurology & neurosurgerymedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Prospective Comparison on Cardiac Iron and Liver Iron by MR In Thalassemia Major Patients Treated with Combination Deferipron–Desferrioxamine Versus …

2010

Abstract Abstract 5164 Introduction: Using T2* MR a randomised placebo controlled study from Sardinia demonstrated combination therapy with deferiprone and desferrioxamine (DFP+DFO) significantly more effective than DFO in improving myocardial iron. One non-randomised study from Sardinia and one observational study from Greece seem to confirm for DFP+DFO therapy the most rapid clearance of cardiac iron. No data are available in literature about prospective comparisons on cardiac iron and function and liver iron in TM patients treated with DFP+DFO versus DFP and DFO in monotherapy. The aim of this multi-centre study was to assess prospectively in a large clinical setting the efficacy of the …

medicine.medical_specialtyCombination therapybusiness.industryThalassemiaImmunologyUrologyPlacebo-controlled studyCell BiologyHematologymedicine.diseaseBiochemistryDeferipronSurgeryBiventricular functionchemistry.chemical_compoundchemistrymedicineCardiac ironLiver ironDeferipronebusiness
researchProduct

Queratitis bacteriana por Moraxella nonliquefaciens

2020

Moraxella keratitis can lead to important complications. Moraxella nonliquefaciens(M. nonliquefaciens) has the worst prognosis. Only three cases of corneal infections due to M. nonliquefaciens have been published. The case is presented of a 79-year-old man with bullous keratopathy, recently affected with severe infectious keratitis. Dense, deep, and central stromal infiltrates and hyphaema were detected. After the identification of M. nonliquefaciens in the culture, and given the progression of the condition, the initial empirical treatment was modified to topical ciprofloxacin and ceftazidime in accordance with the antibiogram, combining oral ciprofloxacin and amoxicillin-clavulanate. Afte…

medicine.medical_specialtyCorneal Infectionbiologybusiness.industryInfectious Keratitismedicine.diseasebiology.organism_classificationDermatologyMoraxella nonliquefaciensKeratitisCiprofloxacinOphthalmologyLeucomamedicineBullous keratopathybusinessMoraxellamedicine.drugArchivos de la Sociedad Española de Oftalmología
researchProduct

Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study

2013

AIM: To investigate clinical and biochemical features of hepatorenal syndrome (HRS), to assess short and long-term survival evaluating potential predictors of early mortality. METHODS: Sixty-two patients with liver cirrhosis and renal failure, defined as a serum creatinine value > 1.5 mg/dL on at least two measurements within 48 h, admitted to our tertiary referral Unit from 2001 to 201, were retrospectively reviewed. Among them, 33 patients (53.2%) fulfilled the revised criteria of the International Ascites Club for the diagnosis of HRS. Twenty-eight patients were treated with combinations of terlipressin and albumin, two with dopamine and albumin, and three with albumin alone. No patients…

medicine.medical_specialtyCreatinineUnivariate analysisCirrhosisHepatologybusiness.industrymedicine.medical_treatmentLiver transplantationmedicine.diseaseGastroenterologySurgerychemistry.chemical_compoundLiver diseasechemistryHepatorenal syndromeInternal medicineAscitesmedicineOriginal Articlemedicine.symptomTerlipressinbusinesshepatorenal syndromemedicine.drug
researchProduct

Differences in cyclic fatigue lifespan between two different heat treated NiTi endodontic rotary instruments: WaveOne Gold vs EdgeOne Fire

2019

Background Aim of this study is to investigate the cyclic fatigue resistance of the Gold treated WaveOne Gold and the Firewire treated EdgeOne Fire instruments. The null hypotesis was that there were no differences between the lifespan of Gold treated and FireWire treated instruments when subjected to cyclic fatigue tests. Material and Methods 40 new NiTi instruments with a length of 25 mm were tested: 20 Wave One Gold Medium (WOG), tip size 35 and variable taper (Dentsply Maillefer, Ballaigues, Switzerland) and 20 Edge One Fire (EOF) (EdgeEndo, Albuquerque, New Mexico) tip size 35 and the same variable taper. A mobile support for the electric handpiece and a stainless-steel block containin…

medicine.medical_specialtyCyclic stressMaterials scienceRoot canal0206 medical engineering02 engineering and technologycyclic fatigue; EdgeOne Fire; endodontics; NiTi; Waveone GoldNiTiOperative Dentistry and Endodontics03 medical and health sciencesReciprocating motion0302 clinical medicinemedicineStatistical analysisGeneral DentistryWaveone GoldOrthodonticsResearchEdgeOne Fire030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Endodonticscyclic fatigue020601 biomedical engineeringendodonticsmedicine.anatomical_structureNickel titaniumUNESCO::CIENCIAS MÉDICASHeat treated
researchProduct

Spanish Consensus on the Prevention and Treatment of Pseudomonas aeruginosa Bronchial Infections in Cystic Fibrosis Patients

2014

Pseudomonas aeruginosa is the main pathogen in bronchopulmonary infections in cystic fibrosis (CF) patients. It can only be eradicated at early infection stages while reduction of its bacterial load is the therapeutic goal during chronic infection or exacerbations. Neonatal screening and pharmacokinetic/pharmacodynamic knowledge has modified the management of CF-patients. A culture based microbiological follow-up should be performed in patients with no infection with P. aeruginosa. At initial infection, inhaled colistin (0,5-2 MU/tid), tobramycin (300 mg/bid) or aztreonam (75 mg/tid) with or without oral ciprofloxacin (15-20 mg/kg/bid, 2-3 weeks) are recommended. In chronic infections, trea…

medicine.medical_specialtyCystic Fibrosismedicine.drug_classAntibioticsAztreonammedicine.disease_causeCystic fibrosisCystic fibrosischemistry.chemical_compoundInternal medicinemedicineTobramycinHumansPseudomonas InfectionsIntensive care medicinebusiness.industryPseudomonas aeruginosaGeneral Medicinemedicine.diseaseAntibiotic treatmentAnti-Bacterial AgentsCiprofloxacinChronic infectionchemistryChronic DiseasePseudomonas aeruginosaDisease ProgressionColistinbusinessBronchial infectionmedicine.drugArchivos de Bronconeumología (English Edition)
researchProduct